Orchard Therapeutics PLC
Wilma Bradbury is an experienced professional with a strong background in supply chain operations, project management, and CMC (Chemistry, Manufacturing, and Controls) within the biopharmaceutical industry. Currently serving as Director at Orchard Therapeutics since 2018, Wilma has held multiple leadership roles, including CMC Launch Lead and Director of Supply Chain Operations & Logistics. Prior to joining Orchard Therapeutics, Wilma held the position of Head of Operations at Hetero Europe S.L., and Head of Supply Chain at Shield Therapeutics plc. Additional experience includes roles at AstraZeneca, ICE Pharma Group, Stravencon Ltd, Lupin (Europe) Limited, and Medeva Pharmaceuticals Inc, showcasing a progression of leadership roles over an extensive career.
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.